Conducting next generation, non-invasive post-cardiac transplant research, XDx proactively implements customized, instrumentation-grade power protection to safeguard irreplaceable patient samples
Franek Technologies has been selected to protect XDx's $900,000 investment in Applied Biosystems 7900 sequence detection systems used in the company's post-cardiac transplant rejection monitoring research.
Based on past experience with brownouts at its research facilities, XDx proactively sought the higher-level power protection offered by Franek Technologies to protect not only its substantial investment in instrumentation, but most importantly, the irreplaceable patient samples that are paramount to testing for acute cellular rejection in post-cardiac transplant patients.
XDx has pioneered AlloMap molecular expression testing, which is a non-invasive method for determining the risk of rejection in heart transplant recipients.
The patient samples processed at the XDx clinical and research laboratories are irreplaceable as they are collected from a patient at a precise moment in time that is defined by the patient's medical condition.
Should a power outage occur during a test run, which typically lasts just under two hours, the sample and all related data are lost without another blood draw and test rerun.
Because the success of AlloMap testing relies on consistent and accurate data, XDx recognized the importance of implementing the higher level of power protection provided by Franek Technologies for all its ABI instrumentation systems.
Since installation, the protected systems have not lost a single patient sample due to power irregularities.
"With Franek Technologies's power protection systems in place, we don't have to worry about the brownouts that we know are going to occur in our labs," explains Elizabeth King, research specialist, XDx.
"We made sure that our instruments were going to run smoothly 24/7, before experiencing any problems".
"We can now run tests, even over the weekend, without a second thought.
"Having this peace of mind allows us to focus on what's really important, our research and ultimately, the long-term health of post-cardiac transplant patients".
"We are proud of the relationship that we have with XDx, which dates back to 2003," says Raymond Hecker, VP, Franek Technologies.
"The company's researchers realise the real risks posed by unconditioned power and have proactively taken steps to protect their instruments and samples.
"We couldn't be happier that they have not experienced a single power-related loss on their protected systems.
"We look forward to providing more power protection solutions for both their clinical and research labs in the future".
Founded in 2000, XDx is a molecular diagnostics company based in South San Francisco, Calif.
Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project.
The company has developed a proprietary new method for non-invasively monitoring the immune system by measuring gene expression in a patients peripheral blood.
The technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering, immune-mediated diseases.
